Biomarkers of prostate cancer sensitivity to the Sendai virus

  title={Biomarkers of prostate cancer sensitivity to the Sendai virus},
  author={A. A. Belova and Anastasia Olegovna Sosnovtseva and Anastasiya V. Lipatova and K. M. Njushko and N. N. Volchenko and Mikhail Belyakov and O. V. Sudalenko and A. A. Krasheninnikov and P V Shegai and Asiya F. Sadritdinova and Maria S Fedorova and Nikolay V. Vorobjov and Boris Y Alekseev and Andrey D. Kaprin and Anna V. Kudryavtseva},
  journal={Molecular Biology},
Metastatic prostate cancer is often associated with either primary or intractable castration-resistant prostate cancer (CRPC), thus justifying the search for entirely new ways of treatment. Oncolytic viruses are able to selectively induce the death of tumor cells without affecting normal cells. A murine Sendai virus has potential to be used as an oncolytic agent. However, tumors vary in their sensitivity to different viruses, prompting us to attempt to identify corresponding biomarkers that… 
4 Citations

Figures and Tables from this paper

Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy
The prospects for using paramyxovirus receptors as biomarkers for successful personalized virotherapy for certain types of cancer and a combination of expression signatures of immune and receptor genes could be used to find a set of oncolytic viruses that are more effective for specific malignancies.
Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses
This review describes a broad spectrum of defects in genes that participate in IFN induction and IFN response pathways that might serve as potential biomarkers to help in identifying individual cancer patients who are likely to benefit from oncolytic virotherapy.
Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer
A bioinformatic analysis of a The Cancer Genome Atlas data and RNA-Seq profiling of a Russian patient cohort is performed to reveal prognostic markers of locally advanced lymph node-negative prostate cancer (lymph nodes-negative LAPC), and genes for the TMPRSS2-ERG prostate cancer molecular subtype are revealed.
Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes
A review of the efficacy and safety of virotherapy and the most promising combinations based on the published clinical data, rather than presenting all oncolytic virus variations, which are discussed in comprehensive literature reviews.


Mechanisms of Oncolysis by Paramyxovirus Sendai
Oncolytic paramyxoviruses are powerful inducers of interferon and other cytokynes promoting antitumor activity of various cell components of the immune response, as well as cytotoxic T lymphocytes.
TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles
The molecular mechanism of the oncolytic activity of HVJ-E, a replication-incompetent hemagglutinating virus of Japan, and the RIG-I/MAVS signaling pathway represents an attractive target for cancer therapy are analyzed.
Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
It is found that ex vivo infection of immature dendritic cells (DCs) with SeV demonstrates their spontaneous maturation and activation, indicating that rSeV could be a powerful immune booster for DC-based cancer immunotherapy that is worth investigating further.
Oncolysis by paramyxoviruses: preclinical and clinical studies
In general, preclinical studies and phase 1–3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases
These results demonstrate the selective targeting and killing of human tumor cells by recombinant SeV technology and greatly advance the reemerging concept of oncolytic virotherapy, which currently appears to rely largely upon a natural preference of certain viruses for cancer cells.
BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
A proof of concept that the tumor cell-killing mechanism via BioKnife may have significant potential to treat patients with MPM that is characterized by frequent uPAR expression in a clinical setting is suggested.
Differential Expression of CHL1 Gene during Development of Major Human Cancers
The role of CHL1 as a potentially novel specific biomarker in the early pathogenesis of two major histological types of renal cancer is supported and suggested that re-expression of the gene on the edge of tumor mass might promote local invasive growth and enable further metastatic spread in ovary, colon and breast cancer.
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
It is shown in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion.
Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.